Column Group’s Revolution Medicines RVMD Stock Holding History

Column Group’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.62K	Hold	46	–	–	0.01%	3
2026 Q1	$4.47K	Hold	46	–	–	﹤0.01%	3
2025 Q4	$3.66K	Hold	46	–	–	﹤0.01%	5
2025 Q3	$2.15K	Hold	46	–	–	﹤0.01%	5
2025 Q2	$1.69K	Hold	46	–	–	﹤0.01%	5
2025 Q1	$1.63K	Hold	46	–	–	﹤0.01%	5
2024 Q4	$2.09K	Hold	46	–	–	﹤0.01%	5
2024 Q3	$2.09K	Hold	46	–	–	﹤0.01%	6
2024 Q2	$1.78K	Hold	46	–	–	﹤0.01%	6
2024 Q1	$1.48K	Hold	46	–	–	﹤0.01%	7
2023 Q4	$1.32K	Sell	46 -1,230,595	-100%	-$29.6M	﹤0.01%	6
2023 Q3	$34.1M	Sell	1,230,641 -1,346,579	-52%	-$39.9M	22.62%	2
2023 Q2	$68.9M	Sell	2,577,220 -2,000,620	-44%	-$49.1M	26.76%	1
2023 Q1	$99.2M	Hold	4,577,840	–	–	35.85%	1
2022 Q4	$109M	Hold	4,577,840	–	–	36.3%	1
2022 Q3	$90.3M	Buy	4,577,840 +182,790	+4%	+$4.02M	19.98%	2
2022 Q2	$85.7M	Buy	4,395,050 +1,047,805	+31%	+$20.4M	18.23%	2
2022 Q1	$85.4M	Hold	3,347,245	–	–	15.83%	3
2021 Q4	$84.3M	Hold	3,347,245	–	–	11.46%	3
2021 Q3	$92.1M	Hold	3,347,245	–	–	10.47%	4
2021 Q2	$106M	Sell	3,347,245 -233,007	-7%	-$8.13M	15.04%	3
2021 Q1	$164M	Hold	3,580,252	–	–	15.74%	3
2020 Q4	$142M	Buy	+3,580,252	New	+$142M	12.86%	4

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Column Group's RVMD Position: Q2 2026 in Review

Column Group held its Revolution Medicines (RVMD) position steady in Q2 2026 at 46 shares worth $8.62K. The position accounts for 0.01% of the portfolio, ranked #3.

Column Group first reported a position in RVMD in Q4 2020 and has held it in 23 quarters since. The position peaked at $164M in Q1 2021. 637 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Column Group held 46 shares of Revolution Medicines worth $8.62K as of Q2 2026.
Column Group left its Revolution Medicines share count unchanged in Q2 2026.
Revolution Medicines made up 0.01% of Column Group's portfolio in Q2 2026, its #3 holding.
Column Group first reported a position in Revolution Medicines in Q4 2020 and has held it in 23 quarters since.
Column Group's Revolution Medicines position peaked at $164M in Q1 2021.
637 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Column Group's 13F filing for Q2 2026, filed 14 Aug 2026.